NARI — Inari Medical Cashflow Statement
0.000.00%
- $4.68bn
- $4.57bn
- $493.63m
Annual cashflow statement for Inari Medical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -1.19 | 13.8 | 9.84 | -29.3 | -1.64 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 1.9 | 7.91 | 26.9 | 32.1 | 28.6 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -6.26 | -21.2 | -14.3 | -21.5 | 2.64 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -4.94 | 1.91 | 25.5 | -14 | 35.9 |
| Capital Expenditures | -3.14 | -5.46 | -13.6 | -9.95 | -6.2 |
| Purchase of Fixed Assets | |||||
| Software Development Costs | |||||
| Other Investing Cash Flow Items | — | -50 | -37.4 | -185 | -51.8 |
| Acquisition of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -3.14 | -55.4 | -51 | -195 | -58 |
| Financing Cash Flow Items | 0.236 | -0.467 | -2.35 | -6.49 | -9.57 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 10.2 | 144 | 4.07 | 177 | 1.17 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 2.14 | 90.6 | -21.9 | -32.5 | -21 |